Pyrroloquinoline quinone ameliorates L-thyroxine-induced hyperthyroidism and associated problems in rats
Pyrroloquinoline quinone ameliorates L-thyroxine-induced hyperthyroidism and associated problems in rats
复制标题
DOI:
10.1002/cbf.3048
复制
发表时间:
2014-08-01
影响因子:
3.6
通讯作者:
Panda, Sunanda
中科院分区:
文献类型:
--
作者:
Kumar, Narendra;Kar, Anand;Panda, Sunanda
Pyrroloquinoline quinone (PQQ) is believed to be a strong antioxidant. In this study, we have evaluated its hitherto unknown role in L-thyroxin (L-T-4)-induced hyperthyroidism considering laboratory rat as a model. Alterations in the serum concentration of thyroxin (T-4) and triiodothyronine (T-3); lipid peroxidation (LPO) of liver, kidney, heart, muscles and brain; in the endogenous antioxidants such as superoxide dismutase, catalase and glutathione and in serum total cholesterol, high-density lipoprotien, triglycerides, serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT) and urea were evaluated. Administration of L-T-4 (500-mu g kg (1) body weight) enhanced not only the serum T-3 and T-4 levels but also the tissue LPO, serum SGOT, SGPT and urea with a parallel decrease in the levels of antioxidants and serum lipids. However, on simultaneous administration of PQQ (5mg kg(-1) for 6 days), all these adverse effects were ameliorated, indicating the potential of PQQ in the amelioration of hyperthyroidism and associated problems. Possibly, the curative effects were mediated through inhibition of oxidative stress. We suggest that PQQ may be considered for therapeutic use for hyperthyroidism after dose standardization. Copyright (C) 2014 John Wiley & Sons, Ltd.